cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
C4 Therapeutics Inc
8 own
5 watching
Current Price
$6.49
$0.05
(0.78%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
173.65M
52-Week High
52-Week High
11.88000
52-Week Low
52-Week Low
1.06000
Average Volume
Average Volume
1.25M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization173.65M
icon52-Week High11.88000
icon52-Week Low1.06000
iconAverage Volume1.25M
iconDividend Yield--
iconP/E Ratio--
What does the C4 Therapeutics Inc do?
We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. --- We were incorporated in October 2015 under the laws of the State of Delaware. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472, and our telephone number is (617) 231-0700.We have one wholly owned subsidiary, C4T Securities Corporation, a Massachusetts corporation. Our website address is www.c4therapeutics.com.
Read More
How much money does C4 Therapeutics Inc make?
News & Events about C4 Therapeutics Inc.
Zolmax
1 year ago
C4 Therapeutics (NASDAQ:CCCC Get Rating) had its price objective trimmed by Bank of America from $11.00 to $5.00 in a report issued on Tuesday , The Fly reports. The firm currently has a neutral rating on the stock. A number of other analysts have also recently commented on CCCC. Morgan Stanley ...
Zolmax
1 year ago
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Rating) Equities researchers at Brookline Capital Management dropped their FY2027 earnings estimates for C4 Therapeutics in a research report issued to clients and investors on Thursday, February 23rd. Brookline Capital Management analyst L. Cann now forecasts ...
Globe Newswire
1 year ago
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today ...
Globe Newswire
1 year ago
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC Degrader, Continues to Progress with Phase 1 ...
Ticker Report
1 year ago
Vickers Vantage Corp. I (NASDAQ:VCKA Get Rating) and C4 Therapeutics (NASDAQ:CCCC Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability...
Frequently Asked Questions
Frequently Asked Questions
What is C4 Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy C4 Therapeutics Inc shares?
plus_minus_icon
How can I buy C4 Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of C4 Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in C4 Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of C4 Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of C4 Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of C4 Therapeutics Inc?
plus_minus_icon
What percentage is C4 Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is C4 Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.49
$0.05
(0.78%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$57.51
$-0.03 (-0.05 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.82
$0.03 (0.52 %)
GENERATION BIO CO
GENERATION BIO CO
$3.50
$0.08 (2.34 %)
Nkarta Inc
Nkarta Inc
$7.04
$0.13 (1.88 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$57.51
$-0.03 (-0.05 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.82
$0.03 (0.52 %)
GENERATION BIO CO
GENERATION BIO CO
$3.50
$0.08 (2.34 %)
Nkarta Inc
Nkarta Inc
$7.04
$0.13 (1.88 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00